Stocktoria
Barinthus Biotherapeutics plc. BRNS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-04-30
Barinthus Biotherapeutics plc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $15.0M | $802,000 | $44.7M | $268,000 |
| R&D expense | $25.6M | $42.2M | $44.9M | $42.4M | $20.4M |
| Operating income | -$70.6M | -$68.0M | -$83.9M | -$4.0M | -$45.2M |
| Interest expense | — | — | $28,000 | $19,000 | $2.7M |
| Income tax | -$175,000 | -$44,000 | -$3.1M | -$4.5M | -$28,000 |
| Net income | -$66.4M | -$61.1M | -$73.3M | $5.3M | -$50.9M |
| EPS (diluted) | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 |
| Operating cash flow | -$48.0M | -$28.9M | -$50.9M | -$14.4M | -$32.6M |
| Free cash flow | -$48.0M | -$29.8M | -$56.3M | -$20.6M | -$33.7M |
| Cash & equivalents | $70.5M | $110.7M | $142.1M | $194.4M | $214.1M |
| Total assets | $98.2M | $160.3M | $214.5M | $270.2M | $280.7M |
| Total liabilities | $23.9M | $30.2M | $27.5M | $27.0M | $28.2M |
| Shareholders' equity | $74.3M | $130.1M | $187.0M | $243.2M | $252.6M |
Source: SEC EDGAR filings · CIK 0001828185 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.